2022 June
archive,date,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive

June 2022

The addition of capivasertib to fulvestrant showed a significant PFS benefit in the original pathway-altered and non-altered subgroups. In the pathway altered subgroup, the median OS with the combination was significantly longer than fulvestrant alone. The expanded biomarker testing suggested that capivasertib predominantly benefits patients with PI3K/AKT/PTEN pathway-altered tumours. (Ref: Howell SJ et al.  Lancet Oncol. June 1, 2022)
#oncologyresearch #clinicaldevelopment


In patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy and checkpoint inhibitor therapy, adagrasib showed an objective response of 42.9%. Tumor shrinkage of any magnitude was observed in 79.5% patients (A). Intracranial tumor shrinkage was also seen (B). The median duration of response was 8.5 months (95% CI 6.2 to 13.8), the median PFS was 6.5 months (95% CI, 4.7 to 8.4) and the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). The results were similar to sotorasib.
(Ref: Jänne PA et al. N Engl J Med. June 3, 2022)
#oncologyresearch #drugdevelopment